CNR Institutional Research Information System

AZZOLINA, ANTONINA

AZZOLINA, ANTONINA  

Istituto per la Ricerca e l'Innovazione Biomedica -IRIB  

Mostra records
Risultati 1 - 20 di 79 (tempo di esecuzione: 0.01 secondi).
Titolo Data di pubblicazione Autore(i) File
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 1-gen-2010 Cervello, M; Bachvarov, D; Cusimano, A; Azzolina, A; Lampiasi, N; Abbaleo, S; Sardina, F; Giannitrapani, L; Mccubrey, Ja; Montalto, G
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 1-gen-2011 Cervello, M; Cusimano, A; Bachvarov, D; Azzolina, A; Mccubrey, Ja; Montalto, G; Lampiasi, N
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 1-gen-2009 Lampiasi, N; Azzolina, A; D'Alessandro, N; Umezawa, K; Mccubrey, Ja; Montalto, G; Cervello, M
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells 1-gen-2005 Cusimano A; Foderà D; Lampiasi N; Azzolina A; Montalto G; Cervello M
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells. 1-gen-2005 Cusimano, A; Foderà, D; Lampiasi, N; Azzolina, A; Montalto, G; Cervello, M
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. 1-gen-2009 Miceli V; Cervello M; Azzolina A; Montalto G; Calabrò M; Carruba G.
Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment 1-gen-2017 Maria Luisa Bondì; Maria Rita Emma; Chiara Botto; Giuseppa Augello; Antonina Azzolina; Francesca Di Gaudio; Emanuela Fabiola Craparo; Gennara Cavallaro; Dimcho Bachvarov; Melchiorre Cervello
Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference 1-gen-2018 Chiara Botto; Giuseppa Augello; Erika Amore; Maria Rita Emma; Antonina Azzolina; Gennara Cavallaro; Melchiorre Cervello; Maria Luisa BondìChiara Botto; Giuseppa Augello; Erika Amore; Maria Rita Emma; Antonina Azzolina; Gennara Cavallaro; Melchiorre Cervello; Maria Luisa Bondì
Cationic Solid-lipid nanoparticles as DNA carriers. 1-gen-2006 Bondì ML; Azzolina A; Craparo EF; Lampiasi N; Giammona G; Cervello M.
Cationic solid-lipid nanoparticles for gene delivery. 1-gen-2006 Bondì ML; Cervello M; Azzolina A; Craparo EF; Lampiasi N; Giammona G.
Combination of DHMEQ and Celecoxib synergistically exert anti-tumoral effects in human hepatoma cells. 1-gen-2011 Lampiasi, N; Azzolina, A; Umezawa, K; Mccubrey, Ja; Montalto, G; Cervello, M
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 1-gen-2008 Cusimano, A; Iovanna, Jl; Dalessandro, N; Azzolina, A; Montalto, G; Cervello, M
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 1-gen-2008 Cusimano, A; Iovanna, Jl; Dalessandro, N; Azzolina, A; Montalto, G; Cervello, M
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells 1-gen-2007 Lampiasi N; DAlessandro N; Umezawa K; Azzolina A; Montalto G; Cervello M
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 1-gen-2007 Lampiasi N; DAlessandro N; Kazuo Umezawa; Azzolina A; Montalto G; Cervello M.
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 1-gen-2011 Cervello M; Bachvarov D; Cusimano A; Sardina F; Azzolina A; Lampiasi N; Giannitrapani L; McCubrey JA; Montalto G.
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. 1-gen-2011 Cervello, M; Bachvarov, D; Cusimano, A; Sardina, F; Azzolina, A; Lampiasi, N; Giannitrapani, L; Mccubrey, Ja; Montalto, G
Development of nimesulide loaded solid lipid nanoparticles. 1-gen-2009 Bondì, Ml; Azzolina, A; Craparo, Ef; Ingo, Gm; Lampiasi, N; Casaletto, Mp; Giammona, G; Cervello, M
DHMEQ and Celecoxib synergistically exert anti-tumoral activities in human liver cancer cells. 1-gen-2011 Lampiasi N; Azzolina A.; Umezawa K.; McCubrey J.A. ; Montalto G. ;M. Cervello
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 1-gen-2008 Lampiasi N; Azzolina A; Valenti F; DAlessandro N; Umezawa K; McCubrey J; Montalto G; Cervello M.